Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2024-02-22 00:00:00 ET · period of report 2024-02-20 · accession 0001683168-24-001134 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-22 | 2024-02-20 | PHIO | Bitterman Robert J | Pres, CEO, Dir | F - Tax | $0.76 | -1,804 | 16.5K | -10% | -$1,371 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2024-02-20 | F | D | 1,804 | $0.76 | 16,490 | D | — | — | (F2) Includes shares of common stock underlying unvested restricted stock units. |